Replimune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. 

CEO
Sushil Patel
CEOSushil Patel
Employees
465
Employees465
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
465
Employees465

REPL Key Statistics

Market cap
1.09B
Market cap1.09B
Price-Earnings ratio
-3.44
Price-Earnings ratio-3.44
Dividend yield
Dividend yield
Average volume
11.86M
Average volume11.86M
High today
$13.40
High today$13.40
Low today
$11.42
Low today$11.42
Open price
$13.00
Open price$13.00
Volume
8.91M
Volume8.91M
52 Week high
$13.90
52 Week high$13.90
52 Week low
$1.50
52 Week low$1.50

Stock Snapshot

With a market cap of 1.09B, Replimune(REPL) trades at $12.00. The stock has a price-to-earnings ratio of -3.44.

During the trading session on 2026-08-09, Replimune(REPL) shares reached a daily high of $13.40 and a low of $11.42. At a current price of $12.00, the stock is +5.1% higher than the low and still -10.4% under the high.

Trading volume for Replimune(REPL) stock has reached 8.91M, versus its average volume of 11.86M.

Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $13.90 and a low of $1.50.

Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $13.90 and a low of $1.50.

REPL News

Investing.com 5h
Replimune in the spotlight: Earnings loom days after FDA approval - Investing.com

...

Replimune in the spotlight: Earnings loom days after FDA approval - Investing.com
Simply Wall St 6h
Replimune Group Wins FDA Approval, Is The Valuation Still Too Rich?

Replimune Group (REPL) stock is back in focus after Robbins LLP announced a securities class action tied to the company’s RP1 melanoma program and the U.S. Food...

Replimune Group Wins FDA Approval, Is The Valuation Still Too Rich?
TipRanks 2d
Replimune Wins FDA Accelerated Approval for TUDRIQEV

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

More REPL News

TipRanks 2d
Wedbush upgrades Replimune to Outperform following FDA decision

As previously reported, Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $19, up from $12. The firm notes the Food and Drug A...

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.